SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2021
|BIMI International Medical Inc.|
|(Exact name of registrant as specified in its charter)|
|(State or other jurisdiction|
|(Commission File Number)||(IRS Employer|
|9th Floor, Building 2,|
Chongqing Corporation Avenue,
Yuzhong District, Chongqing, P. R. China
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code: (8604) 1182209211
|(Former name or former address, if changed since last report)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which registered|
|Common stock, $0.001 par value||BIMI||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 — Submission of Matters to a Vote of Security Holders
At the Registrant’s special meeting of shareholders held on November 5, 2021, the shareholders of the Registrant (the “Shareholders”) voted to (i) approve an amendment to the Registrant’s Certificate of Incorporation to increase the number of Registrant’s authorized shares of common stock (the “Common Stock”) by 150,000,000 to 200,000,000; and (2) grant discretionary authority to the board of directors of the Registrant (the “Board”) to amend the Registrant’s Certificate of Incorporation to effect a reverse stock split of the Common Stock within the range of 1-2 to 1-5 to be determined by the Board and with the reverse stock split to be effective at such time and date, if at all, as determined by the Board, but not later than the first anniversary of its approval by the Shareholders.
1. The votes cast by the Shareholders with respect to the increase of the authorized shares were as follows:
2. The votes cast by the Shareholders with respect to the reverse stock split were as follows:
On November 8, 2021, the Registrant issued a press release announcing shareholder approval of the above two proposals. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
|10.1||Press release dated November 8, 2021|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: November 8, 2021||BIMI International Medical Inc.|
|By:||/s/ Tiewei Song|
|Title:||Chief Executive Officer|